Endo spokesman Kevin Wiggins said the company ran out of space in Chadds Ford, where it leases 185,000 square feet in four buildings. The company has been based in the Delaware County township since its founding from the management-led buyout of a line of pain medicines from DuPont Merck Pharmaceutical Co. in 1997.
Jeff Goggins, senior manag-
ing director for Trammell Crow's Northeast Metro Division in Conshohocken, said his firm began talking in earnest with Endo representatives in August. He would not provide details of the lease, describing it only as "long term."
The new headquarters will consist of two five-story buildings connected by a sky bridge and overlooking a 70-acre lake that used to be a limestone quarry, Goggins said.
It's a big win for Atwater, where just one of 15 planned office buildings totaling 2.6 million square feet has been built over the last decade. That pace of development could change with the completion next fall of a $48 million E-ZPass-only interchange linking the Pennsylvania Turnpike to Route 29 and the Atwater property.
Wiggins said the company was "working with Harrisburg" on possible financial incentives in connection with the project. A spokesman for the Pennsylvania Department of Community and Economic Devel-
opment did not return a call seeking comment Monday.
Endo's announcement is the latest by an area drug company seeking to move into new space. GlaxoSmithKline P.L.C., Iroko Pharmaceuticals L.L.C. and Teva Pharmaceutical Industries Ltd. are building in Philadelphia. In addition, Shire P.L.C., with 1,000 employees in four buildings in the Chesterbrook Corporate Center in Chester County, is evaluating its options.
Contact Mike Armstrong
at 215-854-2980 or email@example.com, or @PhillyInc on Twitter. Read his blog, "PhillyInc," at www.phillyinc.biz.